

Message

From: Calvin Willhite [Ex. 6 Personal Privacy (PP)]
Sent: 4/3/2021 7:49:34 PM
To: Allan H. SMITH [ahsmith@berkeley.edu]; tsujij@exponent.com; Harvey Clewell [hclewell@ramboll.com]; Cohen, Samuel M [scohen@unmc.edu]; Shao, Kan [kshao@indiana.edu]; Bette Meek [bmeek@uottawa.ca]; Michael Dourson [Ex. 6 Personal Privacy (PP)]; Lee, Janice [Lee.JaniceS@epa.gov]; Thayer, Kris [thayer.kris@epa.gov]; Orme-Zavaleta, Jennifer [Orme-Zavaleta.Jennifer@epa.gov]
Subject: SOT Arsenic Symposium
Attachments: Arsenic and cerebral small vessel disease.pdf

I don't know that I can endorse the attached human health observations on arsenic, but if true we can now add dementia to the long list of adverse health outcomes.

This comes as very bad news.

Dr. Tsuji will cover cardiovascular aspects of chronic arsenic intoxication. From the attached it appears there are multiple MOAs and multiple target organs in addition to its inhibition of sulfhydryl enzymes.

One focus of the proposed Symposium is not only the shape(s) of the low-dose aspects of arsenic of which there appear to be many, but also which of the many different adverse outcomes should drive the As health risk assessment.

Hopefully Program Committee will see the importance of the problem.